Search | Clinical Trials Finder

Conditions: Asthma
Interventions: Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more

Conditions: Bioequivalence
Interventions: Oxymetazoline hydrochloride Cream, 1%, Rhofade™ (oxymetazoline) cream, 1%, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: TT-01025-CL; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Ornithine Transcarbamylase Deficiency
Interventions: ARCT-810, Placebo; Biological · Other
Lead sponsor: Arcturus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 8
States / cities: Gainesville, Florida • Minneapolis, Minnesota • New York, New York + 5 more

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 72
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more

Conditions: Healthy Volunteers
Interventions: BMS-986325, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Cypress, California

Conditions: Cytomegalovirus Infection
Interventions: mRNA-1647, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: North Hollywood, California • San Diego, California • Honolulu, Hawaii

Conditions: Major Depressive Disorder
Interventions: CERC-301, Placebo; Drug · Other
Lead sponsor: Avalo Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Culver City, California + 21 more

Conditions: Bronchiectasis
Interventions: 280 mg Arikayce™, Matching Placebo for Cohort 1, 560 mg Arikayce™, Matching Placebo for Cohort 2; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Philadelphia, Pennsylvania

Conditions: Squamous Cell Carcinoma of the Oral Cavity and Oropharynx, Oral Mucositis
Interventions: SGX942, Placebo; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 32
States / cities: Tucson, Arizona • Loma Linda, California • Pomona, California + 29 more

Conditions: Skin and Soft Tissue Infections, Abscess
Interventions: Standard of Care (SoC), Irrisept Delivery System; Device
Lead sponsor: Irrimax Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Keloid
Interventions: Botulinum toxin type A, Vehicle; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Chronic Neuropathic Pain
Interventions: ST-503, Sham (No Treatment); Genetic · Procedure
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 8 more

Conditions: Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts, RAEB
Interventions: rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC); Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years to 81 Years
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 32
States / cities: La Jolla, California • Los Angeles, California • Fleming Island, Florida + 25 more

Conditions: Schizophrenia or Schizoaffective Disorder
Interventions: AMG 581, Placebo, Midazolam; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Glendale, California

Conditions: Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
Interventions: Biological: oral polio vaccine, Comparable Placebo, NA-831, Comparable Placebo of drug, Combination of oral polio vaccine and NA-831, Comparable Placebo of Oral Polio Vaccine and Placebo of drug; Biological · Drug · Combination Product
Lead sponsor: Biomed Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 4 more

Conditions: Facial Neuropathy
Interventions: Lamotrigine, Placebo (for Lamotrigine); Drug
Lead sponsor: Pain and Analgesia Imaging and Neuroscience Group; Other
Eligibility: 18 Years to 60 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Healthy Volunteers
Interventions: Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent), CC-99677; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Miami, Florida • Marlton, New Jersey • Austin, Texas

Conditions: Metastatic Colorectal Cancer (CRC)
Interventions: Drug: Ivonescimab Injection, Drug: Bevacizumab Injection; Drug
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 112
States / cities: Mobile, Alabama • Tuscaloosa, Alabama • Goodyear, Arizona + 94 more

Conditions: Actinic Keratosis
Interventions: Diclofenac sodium, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 30
States / cities: Mesa, Arizona • Tucson, Arizona • Fremont, California + 23 more

Conditions: Plaque Psoriasis
Interventions: TAK-279, Placebo, Apremilast; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 693 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 27
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 24 more

Conditions: Fibromyalgia, Neurocognition
Interventions: Milnacipran, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Insomnia
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Hot Springs, Arkansas + 22 more

Conditions: Covid19
Interventions: IFN beta-1a, Dexamethasone; Drug
Lead sponsor: Faron Pharmaceuticals Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Newton, Massachusetts + 1 more

Search by objective public record fields.

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

A Study Comparing Oxymetazoline 1% Cream to RHOFADE

A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of TT-01025-CL in Healthy Subjects

Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

The Effect of Irrisept for Irrigation of Skin and Soft Tissue Infections (Irrisept USF Study)

Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids

Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective

A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI

A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Participants

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial

Study of Efficacy of Ramelteon in Adults With Chronic Insomnia

Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19